Literature DB >> 10793062

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

G Pruneri1, S Fabris, L Baldini, N Carboni, S Zagano, M A Colombi, G Ciceri, L Lombardi, M Rocchi, R Buffa, A T Maiolo, A Neri.   

Abstract

The t(11;14)(q13;q32) chromosomal translocation, the hallmark of mantle cell lymphoma (MCL), is recurrently found in multiple myelomas (MM) by means of conventional cytogenetics. Unlike MCL, recent molecular studies of MM-derived cell lines with t(11;14) have indicated that the breakpoints are highly dispersed over the 11q13 region; however, the fact that cyclin D1 is generally overexpressed in these cell lines suggests that this gene is the target of the translocation. To evaluate further the involvement of cyclin D1 in MM, we used immunohistochemistry and fluorescence in situ hybridization to investigate cyclin D1 expression and the presence of chromosome 11 abnormalities in a representative panel of 48 MM patients (40 at diagnosis and 8 at relapse). Cyclin D1 overexpression occurred in 12/48 (25%) of cases; combined immunohistochemistry and fluorescence in situ hybridization analyses in 39 patients showed cyclin D1 positivity in all of the cases (7/7) bearing the t(11;14), in two of the 13 cases with trisomy 11, and in one of the 19 cases with no apparent abnormalities of chromosome 11. Our data indicate that the t(11;14) translocation in MM leads to cyclin D1 overexpression and that immunohistochemical analysis may represent a reliable means of identifying this lesion in MM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793062      PMCID: PMC1876932          DOI: 10.1016/S0002-9440(10)65022-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.

Authors:  K Nishida; A Tamura; N Nakazawa; Y Ueda; T Abe; F Matsuda; K Kashima; M Taniwaki
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.

Authors:  M Chesi; P L Bergsagel; L A Brents; C M Smith; D S Gerhard; W M Kuehl
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization.

Authors:  J W Vaandrager; E Schuuring; E Zwikstra; C J de Boer; K K Kleiverda; J H van Krieken; H C Kluin-Nelemans; G J van Ommen; A K Raap; P M Kluin
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

4.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.

Authors:  S Iida; P H Rao; M Butler; P Corradini; M Boccadoro; B Klein; R S Chaganti; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

5.  Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections.

Authors:  M A Vasef; L J Medeiros; L S Yospur; N C Sun; A McCourty; R K Brynes
Journal:  Mod Pathol       Date:  1997-09       Impact factor: 7.842

6.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

7.  The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.

Authors:  J W Vaandrager; P Kluin; E Schuuring
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

8.  Framework YAC contig anchored into a 3.2-Mb high-resolution physical map in proximal 11q13.

Authors:  A Courseaux; P Szepetowski; M Fernandes; C Serizet; Y Kawaguchi; J Grosgeorge; D Perucca-Lostanlen; T B Shows; J A Todd; N J Nowak; P Gaudray
Journal:  Genomics       Date:  1997-02-15       Impact factor: 5.736

9.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.

Authors:  R Richelda; D Ronchetti; L Baldini; L Cro; L Viggiano; R Marzella; M Rocchi; T Otsuki; L Lombardi; A T Maiolo; A Neri
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

10.  Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage.

Authors:  N S Fracchiolla; G Pruneri; L Pignataro; N Carboni; P Capaccio; A Boletini; R Buffa; A Neri
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

View more
  10 in total

Review 1.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

2.  Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.

Authors:  Leticia Quintanilla-Martinez; Marcus Kremer; Katja Specht; Julia Calzada-Wack; Michaela Nathrath; Robert Schaich; Heinz Höfler; Falko Fend
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases.

Authors:  Ioannis Kostopoulos; Mario Cocco; Chiara Ginanneschi; Alessandro D'Amuri; Stefano Lazzi; Alberto Fabbri; Francesco Forconi; Maria Margherita De Santi; Lorenzo Leoncini
Journal:  Virchows Arch       Date:  2006-07-18       Impact factor: 4.064

4.  Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.

Authors:  Ines Martin-Padura; Paola Marighetti; Giuliana Gregato; Alice Agliano; Omar Malazzi; Patrizia Mancuso; Giancarlo Pruneri; Andrea Viale; Francesco Bertolini
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

5.  Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.

Authors:  O Markovic; D Marisavljevic; V Cemerikic; N Suvajdzic; N Milic; M Colovic
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms.

Authors:  Robert Albero; Anna Enjuanes; Santiago Demajo; Giancarlo Castellano; Magda Pinyol; Noelia García; Cristina Capdevila; Guillem Clot; Helena Suárez-Cisneros; Mariko Shimada; Kennosuke Karube; Mónica López-Guerra; Dolors Colomer; Sílvia Beà; José Ignacio Martin-Subero; Elías Campo; Pedro Jares
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

7.  Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review.

Authors:  Somanath Padhi; Renu G'boy Varghese; Anita Ramdas
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

8.  One Patient, Two Uncommon B-Cell Neoplasms: Solitary Plasmacytoma following Complete Remission from Intravascular Large B-Cell Lymphoma Involving Central Nervous System.

Authors:  Joycelyn Lee; Soo Yong Tan; Leonard H C Tan; Hwei Yee Lee; Khoon Leong Chuah; Tiffany Tang; Richard Quek; Kevin Tay; Miriam Tao; Soon Thye Lim; Mohamad Farid
Journal:  Case Rep Med       Date:  2014-02-18

9.  Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.

Authors:  Yu Zhang; Liang Zhou; Yun Leng; Yun Dai; Robert Z Orlowski; Steven Grant
Journal:  Oncotarget       Date:  2017-08-01

10.  Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.

Authors:  Selami K Toprak; Klara Dalva; Merih Kızıl Cakar; Nazmiye Kurşun; Meral Beksaç
Journal:  Turk J Haematol       Date:  2011-04-28       Impact factor: 1.831

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.